Cargando…
Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
BACKGROUND: Tumour immune microenvironment (TIME) of gastrointestinal stromal tumours (GISTs) is largely unknown. METHODS: A total of 81 surgical specimens from 67 patients with advanced GISTs were categorised into treatment groups: tyrosine kinase inhibitor (TKI)-naive, n = 20; imatinib-progressed...
Autores principales: | Yoo, Changhoon, Ryu, Yeon-mi, Kim, Sang-Yeob, Kim, Jihun, Ock, Chan Young, Ryu, Min-Hee, Kang, Yoon-Koo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888806/ https://www.ncbi.nlm.nih.gov/pubmed/31607749 http://dx.doi.org/10.1038/s41416-019-0596-1 |
Ejemplares similares
-
Gastrointestinal Stromal Tumours: An Update
por: Somerhausen, Nicolas De Saint Aubain, et al.
Publicado: (1998) -
Ripretinib for gastrointestinal stromal tumours
Publicado: (2021) -
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
por: Yoo, Changhoon, et al.
Publicado: (2016) -
Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013) -
Gastrointestinal stromal tumour in Meckel's diverticulum
por: Chandramohan, K, et al.
Publicado: (2007)